Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Respiratory disease associated with practolol therapy

A J Marshall, W K Eltringham, D W Barritt

    Lancet (London, England)
    |December 17, 1977
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Gefitinib targets ZAP-70-expressing chronic lymphocytic leukemia cells and inhibits B-cell receptor signaling.

    Cell death & disease·2014
    Same author

    Medical education in the outpatient department.

    Medical teacher·2014
    Same author

    Use of 3-d models in medical education.

    Medical teacher·2014
    Same author

    Vermicomposting in the management of pig-waste in Hong Kong.

    World journal of microbiology & biotechnology·2014
    Same author

    Follicular dendritic cell secreted protein FDC-SP controls IgA production.

    Mucosal immunology·2014
    Same author

    The Diagnosis and Management of Pulmonary Embolism.

    Postgraduate medical journal·2011

    Practolol treatment can cause sclerosing peritonitis and a new respiratory disorder. This condition involves breathing difficulties, fibrotic pleural thickening, and lung lesions, indicating a further practolol syndrome feature.

    Area of Science:

    • Pulmonary Medicine
    • Toxicology
    • Cardiology

    Background:

    • Practolol, a beta-adrenergic blocking agent, was previously used for cardiovascular conditions.
    • Sclerosing peritonitis has been identified as a potential adverse effect of practolol treatment.

    Observation:

    • A cohort of six patients who underwent surgical treatment for practolol-induced sclerosing peritonitis developed a distinct respiratory disorder.
    • The observed respiratory condition was characterized by significant clinical and pathological manifestations.

    Findings:

    • Patients presented with dyspnea (shortness of breath) as a primary symptom.
    • Radiological and pathological examination revealed extensive fibrotic pleural thickening.
    • Lung parenchyma exhibited characteristic lesions, suggesting interstitial lung disease.

    Related Experiment Videos

    Implications:

    • The findings suggest that respiratory disease is an additional manifestation of the broader practolol syndrome.
    • This highlights the need for vigilance regarding pulmonary complications in patients with a history of practolol exposure.
    • Further research into the mechanisms and long-term prognosis of practolol-associated respiratory disease is warranted.